STAT October 28, 2024
Andrew Joseph

The company, Ottimo Pharma, is pursuing one of the hottest approaches in immuno-oncology

LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in years — but David Epstein, who was CEO of Seagen, is back.

Epstein...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
NIH's unfinished business
Lilly blames slower-than-expected growth for 2024 sales miss
AbbVie to write off $3.5B over failed schizophrenia drug

Share This Article